Immunovant Total Assets from 2010 to 2024

IMVT Stock

USD 26.89 0.02 0.07%

Immunovant Total Assets yearly trend continues to be comparatively stable with very little volatility. Total Assets are likely to outpace its year average in 2024. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2019-03-31

Previous Quarter

589.7 M

Current Value

515.7 M

Quarterly Volatility

189.8 M

Covid

Check Immunovant financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immunovant's main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 34.8 M or Other Operating Expenses of 296.8 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 5.8 K. Immunovant financial statements analysis is a perfect complement when working with Immunovant Valuation or Volatility modules.

Check out the analysis of Immunovant Correlation against competitors.

For more information on how to buy Immunovant Stock please use our How to Invest in Immunovant guide.

Latest Immunovant's Total Assets Growth Pattern

Below is the plot of the Total Assets of Immunovant over the last few years. Total assets refers to the total amount of Immunovant assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Immunovant books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Immunovant's Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immunovant's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 666.37 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Immunovant Total Assets Regression Statistics

	Arithmetic Mean	187,375,774
	Geometric Mean	3,251,338
	Coefficient Of Variation	144.02
	Mean Deviation	235,074,717
	Median	113,170
	Standard Deviation	269,864,706
	Sample Variance	72827T
	Range	699.6M
	R-Value	0.85
	Mean Square Error	21138T
	R-Squared	0.73
	Significance	0.000049
	Slope	51,574,629
	Total Sum of Squares	1019577.4T

Immunovant Total Assets History

	2024	699.7 M
	2023	666.4 M
	2022	405.8 M
	2021	515.6 M
	2020	412.5 M
	2019	109.4 M
	2018	405 K

Other Fundumenentals of Immunovant

Intangibles To Total Assets

Immunovant Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Accounts Payable	Total Liab	Total Current Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Net Receivables	Capital Surpluse	Deferred Long Term Liab	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Debt	Common Stock	Property Plant Equipment
Total Assets		1.0	0.91	0.63	0.91	1.0	-0.94	-1.0	-0.95	0.43	0.92	-0.89	0.96	-0.71	0.94	0.96	0.2	0.94	0.91
Total Stockholder Equity	1.0		0.9	0.62	0.9	1.0	-0.94	-1.0	-0.95	0.43	0.92	-0.88	0.96	-0.71	0.94	0.96	0.2	0.94	0.9
Net Tangible Assets	0.91	0.9		0.7	0.95	0.91	-0.98	-0.92	-0.79	0.46	0.97	-0.9	0.97	-0.35	0.97	0.97	0.39	0.97	0.95
Accounts Payable	0.63	0.62	0.7		0.69	0.63	-0.62	-0.64	-0.48	0.95	0.62	-0.53	0.67	-0.22	0.61	0.67	0.09	0.61	0.67
Total Liab	0.91	0.9	0.95	0.69		0.91	-0.92	-0.92	-0.88	0.49	0.99	-0.89	0.96	-0.42	0.98	0.96	0.29	0.98	0.98
Total Current Assets	1.0	1.0	0.91	0.63	0.91		-0.94	-1.0	-0.95	0.43	0.92	-0.89	0.96	-0.71	0.94	0.96	0.2	0.94	0.91
Current Deferred Revenue	-0.94	-0.94	-0.98	-0.62	-0.92	-0.94		0.95	0.84	-0.36	-0.95	0.9	-0.96	0.45	-0.97	-0.96	-0.33	-0.97	-0.94
Net Debt	-1.0	-1.0	-0.92	-0.64	-0.92	-1.0	0.95		0.94	-0.44	-0.94	0.89	-0.97	0.68	-0.95	-0.97	-0.21	-0.95	-0.92
Retained Earnings	-0.95	-0.95	-0.79	-0.48	-0.88	-0.95	0.84	0.94		-0.31	-0.89	0.8	-0.89	0.78	-0.89	-0.89	-0.05	-0.89	-0.88
Net Receivables	0.43	0.43	0.46	0.95	0.49	0.43	-0.36	-0.44	-0.31		0.39	-0.32	0.45	-0.19	0.37	0.45	-0.05	0.37	0.45
Capital Surpluse	0.92	0.92	0.97	0.62	0.99	0.92	-0.95	-0.94	-0.89	0.39		-0.88	0.98	-0.43	0.99	0.98	0.28	0.99	0.99
Deferred Long Term Liab	-0.89	-0.88	-0.9	-0.53	-0.89	-0.89	0.9	0.89	0.8	-0.32	-0.88		-0.89	0.47	-0.94	-0.89	-0.61	-0.94	-0.83
Net Invested Capital	0.96	0.96	0.97	0.67	0.96	0.96	-0.96	-0.97	-0.89	0.45	0.98	-0.89		-0.51	0.98	1.0	0.28	0.98	0.97
Short Long Term Debt	-0.71	-0.71	-0.35	-0.22	-0.42	-0.71	0.45	0.68	0.78	-0.19	-0.43	0.47	-0.51		-0.47	-0.51	0.2	-0.47	-0.43
Capital Stock	0.94	0.94	0.97	0.61	0.98	0.94	-0.97	-0.95	-0.89	0.37	0.99	-0.94	0.98	-0.47		0.98	0.38	1.0	0.97
Net Working Capital	0.96	0.96	0.97	0.67	0.96	0.96	-0.96	-0.97	-0.89	0.45	0.98	-0.89	1.0	-0.51	0.98		0.27	0.98	0.97
Short Term Debt	0.2	0.2	0.39	0.09	0.29	0.2	-0.33	-0.21	-0.05	-0.05	0.28	-0.61	0.28	0.2	0.38	0.27		0.38	0.17
Common Stock	0.94	0.94	0.97	0.61	0.98	0.94	-0.97	-0.95	-0.89	0.37	0.99	-0.94	0.98	-0.47	1.0	0.98	0.38		0.97
Property Plant Equipment	0.91	0.9	0.95	0.67	0.98	0.91	-0.94	-0.92	-0.88	0.45	0.99	-0.83	0.97	-0.43	0.97	0.97	0.17	0.97

Click cells to compare fundamentals

About Immunovant Financial Statements

Immunovant shareholders use historical fundamental indicators, such as Total Assets, to determine how well the company is positioned to perform in the future. Although Immunovant investors may analyze each financial statement separately, they are all interrelated. The changes in Immunovant's assets and liabilities, for example, are also reflected in the revenues and expenses on on Immunovant's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.

		Last Reported	Projected for Next Year
	Total Assets	666.4 M	699.7 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Immunovant Stock Analysis

When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC